| Code | CSB-RA011046MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to GR-1603, designed for research targeting interferon alpha and beta receptor subunit 1 (IFNAR1). IFNAR1 is a critical transmembrane protein that forms part of the type I interferon receptor complex, mediating cellular responses to interferon-alpha and interferon-beta signaling. Upon ligand binding, IFNAR1 associates with IFNAR2 to activate the JAK-STAT signaling pathway, triggering antiviral responses, immune regulation, and antiproliferative effects. Dysregulation of IFNAR1 signaling has been implicated in various pathological conditions, including autoimmune disorders such as systemic lupus erythematosus, viral infections, and certain malignancies where aberrant interferon signaling contributes to disease progression.
The reference antibody GR-1603 has been utilized in immunological research to investigate type I interferon receptor function and signaling mechanisms. This biosimilar provides researchers with a reliable tool for studying IFNAR1 expression, receptor dynamics, and the role of type I interferon pathways in immune responses and disease models. It supports investigations into therapeutic interventions targeting interferon signaling in autoimmune conditions and cancer research.
There are currently no reviews for this product.